Edwards Lifesciences Corp

詳細情報 Edwards Lifesciences Corp 企業名

Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical). It develops transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. Its PASCAL PRECISION and Cardioband transcatheter valve repair systems are commercially available in Europe for mitral and tricuspid valve repair.

Edwards Lifesciences Corpの企業情報



企業コードEW

会社名Edwards Lifesciences Corp

上場日Mar 27, 2000

最高経営責任者「CEO」Mr. Bernard J. Zovighian

従業員数15800

証券種類Ordinary Share

決算期末Mar 27

本社所在地One Edwards Way

都市IRVINE

証券取引所NYSE Consolidated

国United States of America

郵便番号92614

電話番号19492502500

ウェブサイトhttps://www.edwards.com

企業コードEW

上場日Mar 27, 2000

最高経営責任者「CEO」Mr. Bernard J. Zovighian

Edwards Lifesciences Corpの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

--

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+6.56%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

+120.44%

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

--

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

19.91K

+19.18%

Mr. Paul A. Laviolette

Independent Director

11.25K

+45.71%

Dr. David T. Feinberg, M.D.

Independent Director

5.84K

+152.86%

Mr. Nicholas J. (Nick) Valeriani

Independent Chairman of the Board

--

Mr. Kieran T. Gallahue

Independent Director

--

Mr. Donald E. Bobo, Jr.

Corporate Vice President - Strategy and Corporate Development

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

--

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+6.56%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

+120.44%

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

--

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

19.91K

+19.18%

Mr. Paul A. Laviolette

Independent Director

11.25K

+45.71%

収益内訳

通貨: USD更新時刻: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

事業別USD

会社名

収益

比率

Transcatheter Aortic Valve Replacement

1.13B

73.81%

Surgical Heart Valve Therapy

266.80M

17.41%

Transcatheter Mitral and Tricuspid Therapies

134.50M

8.78%

地域別USD

会社名

収益

比率

United States

889.70M

58.07%

Europe

378.20M

24.68%

Rest of the world

169.00M

11.03%

Japan

95.30M

6.22%

事業別

地域別

事業別USD

会社名

収益

比率

Transcatheter Aortic Valve Replacement

1.13B

73.81%

Surgical Heart Valve Therapy

266.80M

17.41%

Transcatheter Mitral and Tricuspid Therapies

134.50M

8.78%

株主

更新時刻: 3 hours ago

株主統計

種類

株主統計

比率

The Vanguard Group, Inc.

12.08%

BlackRock Institutional Trust Company, N.A.

5.26%

State Street Investment Management (US)

4.41%

Wellington Management Company, LLP

3.59%

JP Morgan Asset Management

3.09%

他の

71.57%

株主統計

比率

The Vanguard Group, Inc.

12.08%

BlackRock Institutional Trust Company, N.A.

5.26%

State Street Investment Management (US)

4.41%

Wellington Management Company, LLP

3.59%

JP Morgan Asset Management

3.09%

他の

71.57%

種類

株主統計

比率

Investment Advisor

45.67%

Investment Advisor/Hedge Fund

30.30%

Hedge Fund

6.50%

Pension Fund

2.15%

Research Firm

2.10%

Bank and Trust

1.87%

Sovereign Wealth Fund

1.37%

Individual Investor

0.93%

Endowment Fund

0.83%

他の

8.27%

機関投資家保有株



更新時刻: Wed, Oct 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q3

2564

522.58M

89.01%

-30.68M

2025Q2

2595

528.14M

89.95%

-20.66M

2025Q1

2628

535.29M

91.24%

-19.91M

2024Q4

2597

531.64M

90.42%

-4.10M

2024Q3

2568

511.38M

84.93%

-20.94M

2024Q2

2559

522.19M

86.68%

-12.58M

2024Q1

2572

518.82M

86.18%

-12.08M

2023Q4

2573

509.93M

84.08%

-27.42M

2023Q3

2530

522.96M

86.03%

-18.75M

2023Q2

2517

523.54M

86.35%

-20.02M

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

The Vanguard Group, Inc.

69.74M

11.88%

+793.20K

+1.15%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

30.89M

5.26%

-1.39M

-4.31%

Jun 30, 2025

State Street Investment Management (US)

25.63M

4.37%

-149.08K

-0.58%

Jun 30, 2025

Wellington Management Company, LLP

19.83M

3.38%

-9.31M

-31.95%

Jun 30, 2025

JP Morgan Asset Management

20.09M

3.42%

+3.72M

+22.71%

Jun 30, 2025

Jennison Associates LLC

11.67M

1.99%

+1.58M

+15.71%

Jun 30, 2025

Geode Capital Management, L.L.C.

12.72M

2.17%

+45.55K

+0.36%

Jun 30, 2025

Citadel Advisors LLC

12.73M

2.17%

-650.39K

-4.86%

Jun 30, 2025

Walter Scott & Partners Ltd.

8.91M

1.52%

-150.07K

-1.66%

Jun 30, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 0.00 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

データなし

株式分割



日付

種類

比率

May 07, 2020

Split

1→3

日付

種類

比率

May 07, 2020

Split

1→3

詳細情報 Edwards Lifesciences Corp 企業名

Edwards Lifesciences Corpの企業情報

Edwards Lifesciences Corpの経営陣

収益内訳

株主

機関投資家保有株

株主動向

関連ETF

配当金

株式分割